Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00060437 · ClinicalTrials.gov registry record · Phase 2
Perifosine in Treating Patients With Metastatic, Androgen-Independent Prostate Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
NCT00060437: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00060437 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00060437, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy such as perifosine use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of perifosine in treating patients who have prostate cancer that no longer responds to androgen ablation therapy.
Interventions
- DRUG perifosine
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-10 |
| Est. Completion | 2004-04 |
| Phase | Phase 2 |
What the finished NCT00060437 record still lists
NCT00060437 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which perifosine is the first listed.
NCT00060437 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00060437 about?
NCT00060437 is a clinical study titled "Perifosine in Treating Patients With Metastatic, Androgen-Independent Prostate Cancer". RATIONALE: Drugs used in chemotherapy such as perifosine use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of perifosine in treating patients who have prostate cancer that no longer responds to androgen ablation ther...
What is the current status of trial NCT00060437?
This trial is currently completed. It is a Phase 2 study. The study started on 2003-10. Estimated completion is 2004-04.
What interventions are being tested in trial NCT00060437?
The interventions under investigation include: perifosine (DRUG).
Who is sponsoring clinical trial NCT00060437?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia